Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors

View Full Paper
Ask AI
Bookmark
Share

Authors

QHQingmei HanRLRumeng LiBWBingbing Wen

Discussion

Loading...

Member takes

Overview

Combination therapy enhances apoptosis in myeloproliferative neoplasms, suggesting novel therapeutic strategies against hemato-oncological malignancies.

Key Points

  • Combination therapy significantly enhances apoptosis and reduces cell viability in myeloproliferative neoplasms.
  • Decitabine and ruxolitinib together improve treatment outcomes compared to individual drugs.
  • Xenograft murine model validates the therapeutic effectiveness of combined agents against tumors.
  • Findings highlight the potential of dual therapy as a new strategy for managing acute myeloid leukemia.

Cite This Study

Han et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d91bhttps://doi.org/10.1182/blood-2025-7276
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML2025
  2. 2Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes2025
  3. 3Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms2025
  4. 4Ruxolitinib combined with decitabine-intensified modified busulfan/cyclophosphamide conditioning regimen reduces relapse after allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia2025
  5. 5Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025